Drug Sponsors

Perrigo rejects Mylan’s second unsolicited offer

Monday, April 27, 2015 08:56 AM

Dublin-based Perrigo has rejected a second unsolicited offer from Mylan to acquire all outstanding shares of Perrigo for $60 per share in cash and 2.2 Mylan ordinary shares for each ordinary Perrigo share. Mylan is seeking to ward off an unsolicited offer from Israel-based Teva.  

More... »

Quest Diagnostics

Mylan to commence formal offer to acquire Perrigo

Friday, April 24, 2015 01:21 PM

On April 8, Mylan issued a Rule 2.4 announcement under the Irish Takeover Rules stating that it had made a non-binding proposal to acquire Perrigo for $205 in a combination of cash and Mylan stock for each Perrigo share. The Rule 2.4 announcement followed the delivery of that proposal to Perrigo's chairman on April 6.

More... »


Teva proposes to acquire Mylan for $82 per share in cash and stock

Wednesday, April 22, 2015 12:14 PM

Teva Pharmaceutical Industries has proposed to acquire all of the outstanding shares of Mylan in a transaction valued at $82 per Mylan share, with the consideration to be comprised of approximately 50% cash and 50% stock. The Teva cash and stock proposal provides Mylan stockholders with a substantial premium and immediate cash value, as well as significant potential for future value creation through participation in a financially and commercially stronger company.

More... »

Mylan comments on recent bid speculation

Tuesday, April 21, 2015 07:51 AM

Mylan executive chairman Robert J. Coury has commented on recent media speculation about a takeover bid from Teva.

More... »

Merck chairman, CEO Kenneth C. Frazier becomes PhRMA board chairman

Friday, April 17, 2015 12:40 PM

Kenneth C. Frazier, chairman and CEO of Merck, was elected chairman of the board of the Wash. D.C.-based Pharmaceutical Research and Manufacturers of America (PhRMA). At the board meeting, PhRMA’s president and CEO John J. Castellani announced he will be retiring Jan. 1, 2016. 

More... »

BioRestorative Therapies opens new headquarters, lab facility in New York

Wednesday, April 15, 2015 12:42 PM

BioRestorative Therapies (BRT), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, has relocated its corporate, administrative and laboratory operations to Melville, Long Island, N.Y.

More... »

Incyte to establish European headquarters in Geneva

Wednesday, April 15, 2015 12:41 PM

Incyte, a Wilmington, Del.-based biopharmaceutical company, will establish the new headquarters of Incyte Europe in Geneva, Switzerland. Incyte intends to use Incyte Europe as the base from which it will conduct its European clinical development operations, and expects to occupy the 9,000-square-foot facility by mid-2015.

More... »

Cipher Pharmaceuticals enters U.S. market with Innocutis acquisition

Monday, April 13, 2015 12:21 PM

Cipher Pharmaceuticals, a Canada-based specialty pharmaceutical dermatology company, has acquired Innocutis Holdings, a Charleston, S.C.-based, privately held specialty dermatology company, for $45.5 million in cash.

More... »

Mylan notifies Perrigo of HSR filing regarding proposed acquisition

Monday, April 13, 2015 12:20 PM

Mylan, a global generics and specialty pharmaceutical company, has provided Perrigo, an Irish international manufacturer of over-the-counter pharmaceuticals, with notice of its filing of the pre-merger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division regarding its proposed acquisition of Perrigo, as required by the HSR Act. Mylan proposed to acquire Perrigo for $205 per share in a cash-and-stock transaction on April 6.

More... »

Roche acquires CAPP Medical, strengthens oncology translational research pipeline

Monday, April 13, 2015 12:18 PM

Roche has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and located in Palo Alto, Calif., to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) in blood.

More... »

CenterWatch
CWWeekly

April 27

Doctors, patients in the U.S. and U.K. agree: Mobile health apps are good for our health

AARP teams with Georgia Tech's HomeLab, Pfizer and UnitedHealthcare to test wearables with consumers 50+

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs